Nexalin Technology, Inc.

HOUSTON, TX, Aug. 01, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Justin Van Fleet, CPA, as Chief Financial Officer, effective August 1, 2025.

Mr. Van Fleet brings more than 20 years of experience in public accounting and assurance services, most recently serving as Partner at Marcum LLP (formerly Friedman LLP). In this role, he led the firm’s assurance practice and advised both publicly traded and privately held clients across a wide range of sectors including technology, life sciences, manufacturing, and distribution. He is widely recognized for his integrity, technical expertise, and strategic leadership, particularly in guiding companies through complex financial transactions such as IPOs, mergers, and other corporate events.

Throughout his career, Mr. Van Fleet has built a strong track record of developing robust financial systems, mentoring high-performing teams, and ensuring compliance with the highest professional and regulatory standards. He has worked directly with audit committees and boards to drive transparency, financial integrity, and operational excellence.

Mark White, CEO of Nexalin Technology, commented, “We are thrilled to welcome Justin to the Nexalin executive leadership team. His deep expertise in public accounting, regulatory compliance, and strategic financial management will be invaluable as we scale our operations and continue advancing our groundbreaking neurostimulation platform.”

“Nexalin is at a pivotal moment, with a highly differentiated technology platform that holds enormous promise for treating serious mental health conditions,” said Mr. Van Fleet. “I’m honored to join the team and contribute to the financial discipline and scalability needed to support Nexalin’s ambitious goals. This is an exciting time for the Company, and I look forward to helping drive its next phase of growth and innovation.”

As CFO, Mr. Van Fleet will oversee Nexalin’s financial strategy, planning, and reporting functions as the Company advances its innovative, non-invasive neurostimulation systems through regulatory review and into commercial readiness. Nexalin’s Generation 2 and Generation 3 devices, currently under FDA review, are designed to deliver deep-brain stimulation without drugs, surgery, or invasive procedures—offering a potential breakthrough in the treatment of anxiety, depression, and other chronic mental health conditions.

Mr. Van Fleet holds a Bachelor of Science in Accounting from SUNY New Paltz. He is a licensed CPA in both New York and New Jersey and is an active member of the AICPA, NYSSCPA, and NJCPA. He also serves as Treasurer and Asset Development Committee Member of the Community Foundation of South Jersey.